





Disclaimer

The views and opinions expressed in this session are those of the individual presenter and should not be attributed to the organization with which the presenter is employed or affiliated.



Perspectives for IVD

Background

The regulations in Peru for In Vitro Diagnosis (IVD) are 24 years old: Supreme Decree No. 010-97 (*)

CLV
Technical Specifications
Primary and Secondary
Labeling
Insert

Requirements



- Class M10
- Sub-clasification
 according to usage
 (Hematology, Immunology,
 Chemistry and Biochemistry,
 Nuclear Medicine, Serological,
 Toxicological, Molecular Typing,
 etc.)

Classification





Panorama for IVD

Current Situation

The regulations for IVD are based on DS-010-97 and DIGEMID adopts certain criteria of DS-016-2011 and amendments.

DS-010-1997

DS-016-2011



ISO 13485 requirements or BPM equivalent



Labeling Considerations



IMDRF references for IVD¹



Risk-Based Approach



Differentiated changes such as Major and Minor




Delay in the availability of Products **for Public Access.**

High administrative workload for DIGEMID and the Companies.



Panorama for IVD

Future Situation?





Challenges in IVD Regulation

Change Boosters

Regulations worldwide are changing and evolving...

- IMDRF: Adaptation to technical/scientific progress needed
 - ✓ Combination of Devices/Drugs.
 - ✓ "Companion diagnostics"
 - ✓ Decentralized management of hospital-to-home health alternatives.
 - ✓ Digitalization of health: E-Health and m-Health

IVDR EU

✓ Countries interpreted the rules differently reinforcing the need to establish a regulation interpreted in the same way to standardize criteria.


GLOBALIZATION

✓ Good Regulatory Practices¹ (GRP) and Good Reliance Practices (GReIP)².



Overview of challenges in IVD Regulation


Good principles but with several factors that will be known in the implementation.





IVD Regulation Overview

Modern Regulatory Pathways





Overview of IVD regulation Key additional elements of modern, flexible regulation



- Reliance and Recognition. Crucial concepts that optimize resources of the health authority without lowering the regulatory standard.
- Good Regulatory Practices. To ensure that regulations and standards are convergent where appropriate and administrative practices exist that allow for collaboration.
- **Expedited Ways of Approval and Emergency Use.** To ensure that patients have timely access to innovative treatments.
- Innovative approaches to clinical evidence, such as using accurate clinical databases, **Real World Evidence (RWE)**, and reliance on external data for regulatory decision-making.
- Manufacturer-based Software Pre-Certification Programs.



IVD Regulation

Patient-centered approach

Industry and regulators in the region will need to ensure that patient's access to timely diagnosis and improved healthcare can continue without interruption or delay.





Thank you for your attention

Farm. MBA Janneth Tataje Mego

e-mail: Janneth.tataje@roche.com



Thank you